



#25
CASE LA 24A
11/05/02

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ronald S. Hermenau
Type or print name

Ronald S. Hermenau
Signature

10/28/02
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1617

ROBL ET AL.

Examiner: Bahar, Mojdeh

APPLICATION NO: 09/391,053

FILED: SEPTEMBER 7, 1999

FOR: METHOD FOR TREATING DIABETES EMPLOYING AN AP2
INHIBITOR AND COMBINATION

RECEIVED
NOV 01 2002
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

These references were cited in a search report in a corresponding European application. Copies of these references and the search report are enclosed herewith.

11/06/2002 MPEDPLES 00000001 193880 09391053
01 FC:1806 180.00 CH

A petition pursuant to 37 C.F.R. §1.97(d) is enclosed herewith.


The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Certificate under 37 C.F.R. §1.97(e)(1)

I, the undersigned attorney, hereby certify that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5781



Ronald S. Hermenau
Attorney for Applicants
Reg. No. 34,620

Date: October 28, 2002

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
LA 24A
APPLICATION NO.
09/391,053
APPLICANT
ROBL ET AL.
FILING DATE
SEPTEMBER 7, 1999Group
1617

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

RECEIVED
NOV 01 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Kleitzi et al., J. Cel.Biochem.Suppl., Vol. 15, No. 8, page 70 (XP002209109) (1991)
AS	Melki et al., J. Lipid Res. Vol. 34, No. 9, pgs. 1527-34 (XP001094445) (1991)
AT	


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

1617

CASE LA 24A



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Ronald S. Hermenau
Type or print name

Ronald S. Hermenau
Signature

October 28, 2002
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1617

ROBL ET AL.

Examiner: Bahar, Mojdeh

APPLICATION NO: 09/391,053

FILED: SEPTEMBER 7, 1999

FOR: METHOD FOR TREATING DIABETES EMPLOYING AN AP2
INHIBITOR AND COMBINATION

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED
NOV 01 2002
TECH CENTER 1600/2900

PETITION PURSUANT TO 37 CFR §1.97(d)

Sir:

Consideration of the Information Disclosure Statement submitted concurrently herewith is requested. Please charge Deposit Account No. 19-3880 in the name of Bristol-Myers Squibb Company in the amount of \$130 for payment of the fee for filing this petition.

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-3880 in the name of Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-5781
Date: October 28, 2002

Ronald S. Hermenau
Ronald S. Hermenau
Attorney for Applicants
Reg. No. 34,620